Atopix picks up funding from SR One
Atopix has received an undisclosed investment from SR One, the corporate venture capital arm of GlaxoSmithKline. Also, the company has added Dr. Deborah Harland, a partner at SR One, to its board of directors. Based in the UK, Atopix is a biopharmaceutical company focused on treating allergic disease.
7 October 2014•3 mins read
